Skip to content
Search

Latest Stories

Former NPA director Phil Galt named new Cegedim Rx UK managing director

Former NPA director Phil Galt named new Cegedim Rx UK managing director

Phill Galt replaces Adam Dennett who stepped down from the Cegedim Rx's leadership role after a successful ten-year tenure 

Former superintendent pharmacist and National Pharmacy Association (NPA) director, Phil Galt, has been appointed the new UK managing director for pharmacy software supplier Cegedim Rx.


The position was previously held by Adam Dennett, who resigned after a successful ten-year tenure to pursue a new career outside healthcare, the company said.

Cegedim Rx, the pharmacy entity of Cegedim Healthcare Solutions UK, announced the new appointment this month (April 5).

Tristan de Foucher, head of European operations for Cegedim Group, said: “Adam has been a force of nature in this business for the past 10 years. Under his leadership, the team has continuously and successfully invested in and driven product innovation to stay ahead of the ever-changing demands placed upon community pharmacy.”

Galt has over 20 years of experience as a qualified pharmacist and a successful business leader. He has worked extensively in community pharmacy, focusing on both care delivery and technology implementation.

More recently, Galt simultaneously served as the managing director and superintendent pharmacist for Lindsay & Gilmour Pharmacy, an independent chain comprising 32 locations.

Previously, he held positions as a non-executive director on the board of the National Pharmacy Association Insurance Company (NPAI) and as a director of the Association of Independent Multiple Pharmacies (AIMp).

Galt also served as a trustee for the NPA Health Education Foundation, a charity set up to advance public education in the prevention and proper treatment of disease by encouraging greater research within community pharmacy.

Commenting on his appointment, Phil said: “I know the pressures of delivering frontline care in community pharmacy and just how challenging it can be to juggle this alongside managing a sustainable and profitable business.

“I’m therefore truly looking forward to bringing Cegedim Rx my 20 years of customer experience and industry expertise in order to accelerate the company’s product innovation and revenue growth.”

Foucher expressed his delight in having someone of Galt's caliber and industry experience join the company

“Phil Galt is an industry visionary with a proven track record of execution.

“It is an exciting moment in the life of Cegedim Rx and we welcome his leadership to federate the team behind his expertise, enable enhanced support to pharmacists and deliver better patient outcomes,”  he said.

Cegedim Rx offers a comprehensive suite of pharmacy software solutions, including PMR system Pharmacy Manager, Pharmacy Services and Pharmacy Intelligence Hub.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less